So far so good on 510(k) review
This article was originally published in Clinica
Executive Summary
The median reaction to yesterday’s release by the FDA of its keenly-awaited roadmap for the regulatory tightening of the 510(k) premarket notification (PMN) was one of mild relief, tinged with the suspicion that it’s not all over yet.